Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. more
Time Frame | DNA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -20.26% | 1.96% | 1.74% |
1-Month Return | -32.01% | 1.41% | 1.16% |
3-Month Return | -49.57% | -0.06% | 4.18% |
6-Month Return | -40.51% | 14.64% | 18.97% |
1-Year Return | -43.59% | 9.92% | 28.01% |
3-Year Return | -92.34% | 21.12% | 30.32% |
5-Year Return | -92.48% | 76.06% | 96.32% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 54.18M | 76.66M | 313.84M | 477.71M | 251.46M | [{"date":"2019-12-31","value":11.34,"profit":true},{"date":"2020-12-31","value":16.05,"profit":true},{"date":"2021-12-31","value":65.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.64,"profit":true}] |
Cost of Revenue | - | 15.61M | 129.69M | 204.22M | 108.81M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":7.64,"profit":true},{"date":"2021-12-31","value":63.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":53.28,"profit":true}] |
Gross Profit | 54.18M | 61.05M | 184.15M | 273.49M | 142.64M | [{"date":"2019-12-31","value":19.81,"profit":true},{"date":"2020-12-31","value":22.32,"profit":true},{"date":"2021-12-31","value":67.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.16,"profit":true}] |
Gross Margin | 100.00% | 79.64% | 58.68% | 57.25% | 56.73% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":79.64,"profit":true},{"date":"2021-12-31","value":58.68,"profit":true},{"date":"2022-12-31","value":57.25,"profit":true},{"date":"2023-12-31","value":56.73,"profit":true}] |
Operating Expenses | 125.78M | 198.07M | 2.01B | 2.48B | 814.87M | [{"date":"2019-12-31","value":5.07,"profit":true},{"date":"2020-12-31","value":7.98,"profit":true},{"date":"2021-12-31","value":81.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.83,"profit":true}] |
Operating Income | (71.60M) | (137.03M) | (1.83B) | (2.21B) | (672.23M) | [{"date":"2019-12-31","value":-7159800000,"profit":false},{"date":"2020-12-31","value":-13702700000,"profit":false},{"date":"2021-12-31","value":-182846700000,"profit":false},{"date":"2022-12-31","value":-220895200000,"profit":false},{"date":"2023-12-31","value":-67223100000,"profit":false}] |
Total Non-Operating Income/Expense | (44.90M) | 12.39M | (11.19M) | 107.71M | (165.46M) | [{"date":"2019-12-31","value":-41.69,"profit":false},{"date":"2020-12-31","value":11.5,"profit":true},{"date":"2021-12-31","value":-10.39,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-153.62,"profit":false}] |
Pre-Tax Income | (119.83M) | (124.83M) | (1.84B) | (2.12B) | (892.94M) | [{"date":"2019-12-31","value":-11983500000,"profit":false},{"date":"2020-12-31","value":-12483400000,"profit":false},{"date":"2021-12-31","value":-183812200000,"profit":false},{"date":"2022-12-31","value":-212139900000,"profit":false},{"date":"2023-12-31","value":-89294000000,"profit":false}] |
Income Taxes | 22.00K | 1.89M | (1.48M) | (15.03M) | (71.00K) | [{"date":"2019-12-31","value":1.16,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-78.35,"profit":false},{"date":"2022-12-31","value":-795.5,"profit":false},{"date":"2023-12-31","value":-3.76,"profit":false}] |
Income After Taxes | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (892.87M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-89286900000,"profit":false}] |
Income From Continuous Operations | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (854.25M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-85425300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (892.87M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-89286900000,"profit":false}] |
EPS (Diluted) | - | - | (1.52) | (1.23) | (0.47) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-152,"profit":false},{"date":"2022-12-31","value":-123,"profit":false},{"date":"2023-12-31","value":-47,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DNA | |
---|---|
Cash Ratio | 5.79 |
Current Ratio | 6.11 |
Quick Ratio | 6.11 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DNA | |
---|---|
ROA (LTM) | -21.82% |
ROE (LTM) | -63.02% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DNA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.66 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.52 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DNA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.65 |
P/B | 1.98 |
Price/FCF | NM |
EV/R | 5.85 |
EV/Ebitda | NM |
PEG | NM |
Ginkgo Bioworks Holdings (NYSE: DNA ) just reported results for the first quarter of 2024. Ginkgo Bioworks Holdings reported earnings per share of -8 cents. This met the analyst estimate for EPS of -8 cents. The company reported revenue of $37.94 million. This was 17.58% worse than the analyst estimate for revenue of $46.04 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.
The stock market has been on an incredible run over the past year with tech and growth stocks surging. Traders have piled into many fast-moving companies in hopes of locking in quick trading gains. This excitement has increasingly moved back into the meme stock arena as well. While meme stocks somewhat fell out of fashion in 2022 and 2023, they are firmly back now. Traders gravitate to companies with high short interest, lots of trading volume, and the possibility for rapid price movements. With interest rates remaining high, however, and the economy seemingly slowing down, traders are starting to dial back some risk. The stock market notably cooled off in April and things could get even bumpier heading toward this fall’s presidential election. With this in mind, traders might want to move out of some meme stocks before the going gets tougher. These are three meme stocks to sell today before prices plunge. Ginkgo Bioworks (DNA) Source: T. Schneider / Shutterstock.com Ginkgo Bioworks (NYSE: DNA ) is a specialty chemical company that operates primarily in the healthcare and life sciences space.
There’s the age-old adage, “ You have to spend money to make money .” But then again, what if you could spend pennies and get back dollars? This is the promise of penny stocks , many of which today, trade under a dollar and have relatively small market capitalizations. Yet, not all is as easy as money in, money out. While penny stocks represent a relatively cheap way to buy a large number of shares, there’s no guarantee the value of the company will increase. This is partly due to the esoteric nature of how stocks are valued, as they are a combination of emotions like fear and greed, while also relying on mathematical predictions for validity. Thus, penny stocks can present extreme risk when purchased in large quantities while hoping for a skyrocketing price. For those investors who can stomach the risk, here are three high-potential penny stocks to look out for this year. Jaguar Health (JAGX) Source: shutterstock.com/Champhei Trading currently at 27 cents and with a market cap of $74 million, Jaguar Health (NASDAQ: JAGX ) sits firmly inside the penny stock category.
To scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo''s Plant Trait Services, Protein Services, and Deployment Capabilities. JONESBORO, Ark. and BOSTON, May 7, 2024/ PRNewswire/-- GreenLab, an emerging next generation plant-biotechnology company…
Ginkgo Bioworks Holdings (DNA) share price today is $0.7609
Yes, Indians can buy shares of Ginkgo Bioworks Holdings (DNA) on Vested. To buy Ginkgo Bioworks Holdings from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ginkgo Bioworks Holdings (DNA) via the Vested app. You can start investing in Ginkgo Bioworks Holdings (DNA) with a minimum investment of $1.
You can invest in shares of Ginkgo Bioworks Holdings (DNA) via Vested in three simple steps:
The 52-week high price of Ginkgo Bioworks Holdings (DNA) is $2.54. The 52-week low price of Ginkgo Bioworks Holdings (DNA) is $0.74.
The price-to-earnings (P/E) ratio of Ginkgo Bioworks Holdings (DNA) is NM
The price-to-book (P/B) ratio of Ginkgo Bioworks Holdings (DNA) is 1.98
The dividend yield of Ginkgo Bioworks Holdings (DNA) is 0.00%
The market capitalization of Ginkgo Bioworks Holdings (DNA) is $1.26B
The stock symbol (or ticker) of Ginkgo Bioworks Holdings is DNA